kabutan

Chiome Bioscience Inc.(4583) Summary

4583
TSE Growth
Chiome Bioscience Inc.
107
JPY
-4
(-3.60%)
Mar 13, 3:30 pm JST
0.67
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
108
Mar 13, 10:21 pm JST
Summary Chart Historical News Financial Result
PER
PBR
6.71
Yield
ー%
Margin Trading Ratio
946.00
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
110 JPY 0.69 USD
Previous Close Mar 12
111 JPY 0.69 USD
High Mar 13, 9:00 am
110 JPY 0.69 USD
Low Mar 13, 9:52 am
107 JPY 0.67 USD
Volume
642,300
Trading Value
0.07B JPY 0.44M USD
VWAP
108.59 JPY 0.68 USD
Minimum Trading Value
10,700 JPY 67 USD
Market Cap
7.43B JPY 0.05B USD
Number of Trades
150
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Mid
1-Year Average
315
1-Year High Jun 3, 2025
2,216
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 0 5,822,700
Feb 27, 2026 0 5,399,400
Feb 20, 2026 0 5,292,200
Feb 13, 2026 0 5,068,100
Feb 6, 2026 0 4,991,800
Company Profile
Chiome Bioscience Inc. is a drug discovery venture originating from RIKEN. The company specializes in proprietary antibody production technology and generates revenue through licensing.
Sector
Pharmaceuticals
Chiome Bioscience Inc. focuses on developing drug candidates for diseases with high unmet medical needs and supporting antibody drug discovery research, utilizing its core proprietary antibody production technology, the ADLib system. The company's main business area covers upstream processes from basic and exploratory research to preclinical development and early clinical development, with a basic strategy of early out-licensing of development candidate antibodies. In its drug discovery support business, Chiome Bioscience Inc. offers protein expression and purification services as well as antibody production services. The company integrates multiple antibody production technologies to maximize its antibody production capabilities. Chiome Bioscience Inc. has several in-house pipelines, including CBA-1205 and CBA-1535, and is actively promoting new drug discovery projects.